10. (Amended) A composition according to claim 1, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

## **REMARKS**

Entry of this preliminary amendment is requested at the U.S. Patent and Trademark Office's earliest convenience.

Respectfully submitted,

FAY, SHARPE, FAGAN, MINNICH & McKEE, LLP

By:

Richard M. Klein Reg. No. 33,000

1100 Superior Avenue

Seventh Floor

Cleveland, Ohio 44114 Telephone: 216-861-5582 Facsimile: 216-241-1666

E-mail: rklein@faysharpe.com

Attachment - Version With Markings to Show Changes Made

lab429a.wpd

Attorney Docket No.: YAM 2 0013

## **VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Please amend claims **8**, **9** and **10** (i.e. additions are underlined and deletions are bracketed) to read as follows:

## IN THE CLAIMS:

- 8. (Amended) A composition according to [any of claims 1 and 4 to 7] <u>claim 1</u>, wherein the C-terminus of the adrenomedullin is amidated.
- 9. (Amended) A composition according to [any of claims 1 and 4 to 7] <u>claim 1</u>, wherein Gly is added to the C-terminus of the adrenomedullin.
- 10. (Amended) A composition according to [any of claims 1 and 4 to 7] <u>claim 1</u>, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.